Pfizer keen on therapeutic vaccines and stem cells
This article was originally published in Scrip
Executive Summary
Pfizeris looking to build its position in therapeutic vaccines and regenerative medicine, "all keen areas to look for partnering", its R&D head Dr Martin Mackay told executives at the recent JP Morgan healthcare conference. The company would also like more biotech deals and platform technologies, said Dr MacKay, who joined as R&D head in late 2007.